Literature DB >> 29485330

Cancer patients' experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis.

Naima B Benelhaj1, Ann Hutchinson2, Anthony M Maraveyas1,3, Julie D Seymour2, Muhammad Waqas Ilyas4, Miriam J Johnson2.   

Abstract

BACKGROUND: Cancer-associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6 months. Most studies focus on prophylaxis and treatment; few have explored the patients' experience. AIMS: To identify and synthesise the available literature concerning patients' experience of cancer-associated thrombosis.
DESIGN: Systematic literature review and qualitative thematic synthesis. DATA SOURCE: MEDLINE, Embase, CINAHL, PsycINFO (until 10/2016; limited to English) were searched. Eligible papers were qualitative studies of adult patients' experience of cancer-associated thrombosis. Two researchers screened titles/abstracts/papers against inclusion criteria with recourse to a third for disagreements. Critical Appraisal Skills Programme qualitative checklist tool was used for quality appraisal.
RESULTS: A total of 1397 articles were identified. Five qualitative studies (total n = 92; age range 32-84 years) met the inclusion criteria. Participants had various cancer types. Most had advanced disease and were receiving palliative care. Four major themes emerged from the data: knowledge deficit (patients and clinicians), effects of cancer-associated thrombosis (physical and psychological), effects of anticoagulation and coping strategies.
CONCLUSION: The cancer journey is difficult in itself, but thrombosis was an additional, frightening and unexpected burden. Although the association between cancer and thromboembolism is well-known, cancer patients are not routinely educated about the risk or warning symptoms/signs of thromboembolism which may otherwise be misattributed to the cancer by patient and clinician alike. This systematic review highlights the impact of cancer-associated thrombosis on the lives of cancer patients, and calls for education for patients and clinicians to be part of routine care and further work to address this patient priority.

Entities:  

Keywords:  Venous thromboembolism; cancer-associated thrombosis; patient experience; qualitative

Mesh:

Year:  2018        PMID: 29485330     DOI: 10.1177/0269216318757133

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  6 in total

1.  Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre.

Authors:  Kristen McAlpine; Rodney Breau; Marc Carrier; Philippe Violette; Christopher Knee; Ilias Cagiannos; Christopher Morash; Luke Lavallée
Journal:  Can J Surg       Date:  2020-11-30       Impact factor: 2.089

2.  Thrombosis, cancer, and COVID-19.

Authors:  Norman Brito-Dellan; Nikolaos Tsoukalas; Carme Font
Journal:  Support Care Cancer       Date:  2022-05-14       Impact factor: 3.359

3.  Implications of Bed Rest for Patients with Acute Deep Vein Thrombosis: A Qualitative Study.

Authors:  Jian-Shi Du; Dong-Mei Han; Jian-Mei Gong
Journal:  Patient Prefer Adherence       Date:  2020-09-18       Impact factor: 2.711

Review 4.  Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner.

Authors:  Amye M Harrigan; Josée Rioux; Sudeep Shivakumar
Journal:  Curr Oncol       Date:  2022-09-08       Impact factor: 3.109

5.  Use of antithrombotics at the end of life: an in-depth chart review study.

Authors:  Bregje A A Huisman; Eric C T Geijteman; Jimmy J Arevalo; Marianne K Dees; Lia van Zuylen; Karolina M Szadek; Agnes van der Heide; Monique A H Steegers
Journal:  BMC Palliat Care       Date:  2021-07-16       Impact factor: 3.234

6.  Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.

Authors:  Ann Hutchinson; Sophie Rees; Annie Young; Anthony Maraveyas; Kathryn Date; Miriam J Johnson
Journal:  Palliat Med       Date:  2018-11-29       Impact factor: 4.762

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.